Journal: mAbs

Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody

doi: 10.1080/19420862.2018.1486946

Figure Lengend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

Article Snippet: Human breast cancer cell line BT-474 (HTB-20), MDA-MB-175VII (HTB-25), SK-BR-3(HTB-30) and HCC1419(CRL-2326) are HER2-positive cell lines, which were obtained from the ATCC, and HCC1419 is trastuzumab-resistant human breast cancer cell line.

Techniques: Activity Assay

Journal: mAbs

Article Title: Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody

doi: 10.1080/19420862.2018.1486946

Figure Lengend Snippet: ADCC activity evaluation of anti-HER2 antibodies on four target cancer cells.

Article Snippet: Human breast cancer cell line BT-474 (HTB-20), MDA-MB-175VII (HTB-25), SK-BR-3(HTB-30) and HCC1419(CRL-2326) are HER2-positive cell lines, which were obtained from the ATCC, and HCC1419 is trastuzumab-resistant human breast cancer cell line.

Techniques: Activity Assay

Journal: Cancers

Article Title: SLMP53-2 Restores Wild-Type-Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma

doi: 10.3390/cancers11081151

Figure Lengend Snippet: SLMP53-2 inhibits the growth of mutp53-Y220C-expressing tumor cells with no genotoxicity, leading to the differential expression of genes involved in cell cycle and death, lipid metabolism, and endoplasmic reticulum (ER) stress. ( A ) Concentration-response curves for SLMP53-2 in human non-tumoral HFF-1 and tumor mutp53-Y220C-expressing HuH-7 and HCC1419 cells, analyzed by sulforhodamine B (SRB) assay after 48 h treatment with 3.12–50 µM SLMP53-2. Data are mean ± SEM ( n = 5); * p < 0.05, extra sum-of-squares F test. ( B ) IC 50 values of SLMP53-2 and APR-246 in HuH-7 and HCC1419 cells were determined by SRB assay after 48 h treatment with 3.12–50 µM SLMP53-2 or APR-246. Data are mean ± SEM ( n = 5); * p < 0.05, two-way ANOVA with Sidak’s multiple comparison test. ( C ) Effect of SLMP53-2 in HuH-7 cell colony formation, analyzed after 14 days incubation with SLMP53-2; a representative experiment is shown. Data are mean ± SEM ( n = 5); values significantly different from DMSO: * p < 0.05, one-way ANOVA with Dunnett’s multiple comparison test. ( D ) Levels of γH2AX in HuH-7 cells treated with SLMP53-2; 50 µM etoposide was used as a positive control (PC). ( E ) Levels of mutp53 phosphorylation at Ser15 in HuH-7 cells treated with 14 µM SLMP53-2. In ( D , E ), immunoblots represent one of three independent experiments; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. ( F ) Top enriched biological pathways grouped by broad categories based on Ingenuity Pathway Analysis (IPA) starting from the dataset of differentially expressed genes (DEGs) from HuH-7 cells treated with 28 µM SLMP53-2. The number of features for each functional annotation is given in parenthesis. The score combines the log10 p -value and predicted pathway activation or repression status of the corresponding pathway/process, respectively for positive and negative score. The different colors correspond to the different functional annotation categories. ( G ) Top scoring upstream regulators inferred from the same gene expression dataset. The score is the log10 p -value of the predicted activation status. ( H ) Gene expression changes of NUPR1 (blue) and ATF4 (yellow) target genes in SLMP53-2-treated HuH-7 cells.

Article Snippet: Human non-small cell lung carcinoma NCI-H1299, breast ductal carcinoma HCC1419, and non-tumorigenic foreskin fibroblast HFF-1 cell lines were purchased from ATCC (Rockville, MD, USA).

Techniques: Expressing, Concentration Assay, Sulforhodamine B Assay, Incubation, Positive Control, Western Blot, Functional Assay, Activation Assay

Journal: American Journal of Cancer Research

Article Title: Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines

doi:

Figure Lengend Snippet: A panel of 12 parental and derived BCCLs were tested for trastuzumab response. Cells were classified as sensitive (S) or resistant (R) by testing cell proliferation in the presence and absence of 15 µg/ml trastuzumab for 7 days. Response to trastuzumab was quantified by calculating the fold change in the growth rate (∆GR) of the treated cells relative to the non-treated cells. In all cases resistance was defined as a response of ≤ 1.2 in growth rate

Article Snippet: The cell lines AU-565 (CRL-2351) adenocarcinoma, BT-474 (HTB-20) ductal carcinoma, HCC1419 (CRL-2326) ductal carcinoma, HCC1569 (CRL-2330) metaplastic carcinoma, HCC1954 (CRL-2338) ductal carcinoma, MDA-MB-361 (HTB-27) adenocarcinoma, SK-BR-3 (HTB-30) adenocarcinoma, and UACC-812 (CRL-1897) ductal carcinoma were obtained from the American Type Culture Collection.

Techniques: Derivative Assay

Journal: American Journal of Cancer Research

Article Title: Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines

doi:

Figure Lengend Snippet: Amplification signal of the HER2 gene as determined by FISH. BCCL that showed ratio > 2.0 and > 4 HER2 copies were labeled as amplified, and those cases with ratio < 2.0 and 4-6 HER2 copies were determined as equivocal. Heterogeneity was observed as the percentage of tumor cells with ratio < 2.0 and < 4 HER2 copies

Article Snippet: The cell lines AU-565 (CRL-2351) adenocarcinoma, BT-474 (HTB-20) ductal carcinoma, HCC1419 (CRL-2326) ductal carcinoma, HCC1569 (CRL-2330) metaplastic carcinoma, HCC1954 (CRL-2338) ductal carcinoma, MDA-MB-361 (HTB-27) adenocarcinoma, SK-BR-3 (HTB-30) adenocarcinoma, and UACC-812 (CRL-1897) ductal carcinoma were obtained from the American Type Culture Collection.

Techniques: Amplification, Labeling